Kymera Therapeutics

Yahoo Finance • 2 days ago

Kymera (KYMR) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Feb. 26, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Nello MainolfiChief Medical Officer — Jared GollobChief Financial Officer — Bruce Jacobs Need a quote from a Motle... Full story

Yahoo Finance • 3 months ago

Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering

WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today an... Full story

Yahoo Finance • 3 months ago

Kymera Therapeutics Reaches Analyst Target Price

In recent trading, shares of Kymera Therapeutics Inc (Symbol: KYMR) have crossed above the average analyst 12-month target price of $38.69, changing hands for $40.49/share. When a stock reaches the target an analyst has set, the analyst l... Full story

Yahoo Finance • 3 months ago

Kymera Therapeutics Announces Proposed Public Offering

WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today an... Full story

Yahoo Finance • 3 months ago

Kymera jumps on early-stage data for eczema candidate KT-621

[a girl scratches the skin on the elbow of her arm, redness is atopic dermatitis, the girl s face is not visible] Evgeniia Gordeeva * Kymera Therapeutics (KYMR [https://seekingalpha.com/symbol/KYMR]) is up ~51% in Monday trading after r... Full story

Yahoo Finance • 3 months ago

Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent?

Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in eczema. Continue Reading... Full story

Yahoo Finance • 3 months ago

Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis

KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation from healthy volunteers to atopic dermatit... Full story

Yahoo Finance • 3 months ago

Healthcare Names Post Strong After-Hours Moves: KYMR, OCUL, POAI Among Top Gainers

(RTTNews) - Several healthcare and biotech names posted notable gains in Friday's after-hours trading session, with momentum driven by clinical updates, recent announcements, and technical rebounds. Kymera Therapeutics Inc. (KYMR) surged... Full story

Yahoo Finance • 3 months ago

Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025

Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advan... Full story

Yahoo Finance • 3 months ago

Here Are Wednesday’s Top Wall Street Analyst Research Calls: DHL Group, NetApp, Nutanix, Oracle, Snowflake, Urban Outfitters, Zscaler and More

Bet_Noire / iStock via Getty Images Quick Read After a mixed start on Tuesday, all the major indices closed higher as hopes for a December rate cut rose. With the market holiday on Thursday and an early close for Friday, trading could re... Full story

Yahoo Finance • 3 months ago

Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 Completed dosing in KT-621 BroADen Phase 1b AD trial with data to be reporte... Full story

Yahoo Finance • 3 months ago

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

WATERTOWN, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today an... Full story

Yahoo Finance • 4 months ago

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today an... Full story

Yahoo Finance • 4 months ago

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025

WATERTOWN, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will rep... Full story

Yahoo Finance • 4 months ago

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically active therapies KT... Full story

Yahoo Finance • 4 months ago

Kymera added to Citi catalyst watch list on atopic dermatitis asset data readout

[Wall street.] bodrumsurf * Citi has added Kymera Therapeutics (NASDAQ:KYMR [https://seekingalpha.com/symbol/KYMR]) to its 90-day catalyst watch list ahead of a phase 1b data release expected in November for its oral STAT6 degrader KT-6... Full story

Yahoo Finance • 5 months ago

Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses

Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621’s oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track to report d... Full story

Yahoo Finance • 6 months ago

Why Kymera (KYMR) Could Be One of Biotech’s Most Interesting Growth Stories?

Kymera Therapeutics Inc. (NASDAQ:KYMR) is one of the best high-beta stocks to buy now. The company currently commands an optimistic outlook, with management remaining confident in achieving key clinical endpoints and biomarker data. This... Full story

Yahoo Finance • 6 months ago

Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary

WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today a... Full story

Yahoo Finance • 6 months ago

Wednesday's ETF with Unusual Volume: FYC

The First Trust Small Cap Growth AlphaDEX Fund ETF is seeing unusually high volume in afternoon trading Wednesday, with over 111,000 shares traded versus three month average volume of about 27,000. Shares of FYC were up about 0.4% on the... Full story